IL2 and melanoma: This marked the beginning of an extended quest to identify immune-based antitumor regimens, leading to the FDA approval of adjuvant therapy in stage III melanoma with high-dose interferon in 1996 and of high-dose bolus IL-2 for advanced melanoma in 1998.